334 related articles for article (PubMed ID: 12195454)
1. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[TBL] [Abstract][Full Text] [Related]
2. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
7. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
10. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
12. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
Kobelt G; Jönsson L; Miltenburger C; Jönsson B
Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
[TBL] [Abstract][Full Text] [Related]
14. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
16. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
17. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
Wu X; Dastidar P; Kuusisto H; Ukkonen M; Huhtala H; Elovaara I
Acta Neurol Scand; 2005 Oct; 112(4):242-7. PubMed ID: 16146494
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required.
Prescrire Int; 2000 Aug; 9(48):110-1. PubMed ID: 11067719
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
20. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
